What this means
This is a planned study of an astaxanthin supplement in people over 50. It has not started recruiting, and no results have been posted yet, so it cannot show whether the supplement helps.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 50 and over · Older adults aged 50 and above, planned groups not yet enrolled
- Where
- Not listed
The science
- Registered title
- Haematococcus Pluvialis Astaxanthin for Brain Aging
- Trial ID
- NCT07379437 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Brain Aging
- What is tested
- Low-Dose AST, High-Dose AST, Placebo
- Sponsor
- Capital Medical University
- Ages
- 50 Years to no maximum
- Dates
- First posted Jan 30, 2026 · updated Jan 30, 2026
Registry summary
We recruit community-dwelling older adults aged 50 and above for a 6-month intervention. Participants are divided into three groups:
Placebo Group, Low-Dose Group ( 6 mg/d Haematococcus pluvialis Astaxanthin), High-Dose Group (12 mg/d Haematococcus pluvialis Astaxanthin).
Peripheral blood samples and Other tests are collected at baseline, 3 months, and 6 months to measure mitochondrial function and oxidative stress levels.
Assessments include: 1.Cognitive \& Neurophysiological Assessment: Using the MoCA (Montreal Cognitive Assessmentscale) and ERP (specifically P300) monitoring. 2.Brain Imaging: MRI (Magnetic resonance imaging) is used to analyze changes in brain function. 3.Metabolomics: A series of laboratory techniques are used to analyze routine metabolic indices, plasma astaxanthin, mitochondrial function, oxidative stress markers, and cognition-related neurobiomarkers.